People · Operator
Named in public records as an officer, director or promoter · active 2014–2014 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Adaptimmune Ltd | — | Biotechnology | Series D+ | $103.8M | $4.3B | 2014 |
Ian Laing at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ian Laing on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ali Behbahani | 1 | 17 |
| Peter Thompson | 1 | 16 |
| David Mott | 1 | 9 |
| Elliott Sigal | 1 | 2 |
| Dr. Jonathan Knowles | 1 | 1 |
| James Noble | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.